https://doi.org/10.1016/j.vaccine.2019.09.099
Our analysis included 14 Asian countries that were estimated to have a total of 850,000 choleracases and 25,500 deaths in 2015 While, the WHO cholera report documented around 60,000 cholera casesand 28 deaths. We estimated around $20.2 million (I$74.4 m...illion) in out-of-pocket expenditures, $8.5million (I$30.1 million) in public sector costs, and $12.1 million (I$43.7 million) in lost productivity in2015. Lost productivity due to premature deaths was estimated to be $985.7 million (I$3,638.6 million).Our scenario analyses excluding mortality costs showed that the economic burden ranged from 20.3%($8.3 million) to 139.3% ($57.1 million) in high and low scenarios when compared to the base case sce-nario ($41 million) and was least at 10.1% ($4.1 million) when estimated based on cholera cases reportedto WHO
more
Vaccine Management in Indonesia
Circulating vaccine-derived poliovirus type 2 in Angola
Ebola virus disease in Democratic Republic of the Congo
Dengue fever in Côte d’Ivoire
Humanitarian crisis in north-east Nigeria.
The Global Vaccine Action Plan (GVAP) 2011-2020, endorsed by Member States during the May 2012 World Health Assembly, has set ambitious targets to improve access to immunization and tackle vaccine-preventable diseases. This responsibility has been translated into firm commitments in February 2016, t...hrough the signature of the Addis Declaration on Immunization (ADI) by African Ministers and subsequently endorsed by the Heads of States from across Africa at the 28th African Union Summit held in January 2017. This commitment from the highest level of government comes as a catalyst to immunization efforts on the continent to deliver on the promise of universal immunization
more
COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator
The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
COVAX is co-led by Gavi, the Coalition for Epide...mic Preparedness Innovations (CEPI) and WHO. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.
more
AMSP opens COVID-19 vaccines pre-orders for 55 African Union Member States
Find out how many vaccine doses have been given in your country using WHO’s COVID-19 dashboard
The guide explains how vaccines work and answers your common questions as well as providing up-to-date information on the current approved COVID-19 vaccinations in the UK.
This guide was written in January 2021 and updated in March 2021 and is accurate at the time of publishing. Information will b...e updated as it becomes available.
more
Information about vaccine administration
WHO's 'Vaccine Explained' series features illustrated articles on vaccine development and distribution. Learn more about vaccines from the earliest of research stages to their rollout in countries.
Availble in different languages
Child and adolescent vaccine safety report
This report on the safety of COVID-19 vaccination in children and adolescents in Argentina includes data from the start of the adolescent campaign
in Argentina, includes data reported since the start of the campaign in adolescents (28 July 2021) and in ch...ildren aged 3-11 years (12 October 2021) until 6 AM on 31 October 2021.
more
Vaccinator's Manual SINOPHARM Vaccine - 28 FEBRUARY 2021
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...of five leading vaccine manufacturers, AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc. It also includes for the first time an assessment of the two largest Chinese vaccine producers, China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Sinovac Biotech Ltd. (Sinovac).
more
WHO lists 9th COVID-19 vaccine for emergency use to expand vaccination access in low-income countries, 17 December 2021
The introduction of vaccines for coronavirus disease 2019 (COVID-19) added another measure to the existing set of
recommended preventive measures (wearing a mask in public, keeping a distance from other people and regular handwashing). The roll-out of the vaccines, however, raised concerns that vac...cination may lead to lower adherence to the existing
preventive measures. The advice from the World Health Organization (WHO) was to continue these public health and
social measures after being vaccinated.1 However, evidence from other epidemics suggests that there is lower adherence to
preventive measures when some level of protection exists (for example, individuals who use human immunodeficiency virus
pre-exposure prophylaxis
more
Rabies is a vaccine-preventable viral disease which occurs in more than 150 countries and territories. Dogs are the source of the vast majority of human rabies deaths, contributing up to 99% of all rabies transmissions to humans.
Rabies is a vaccine-preventable, zoonotic, viral disease affecting the central nervous system. Once clinical symptoms appear, rabies is virtually 100% fatal. In up to 99% of cases, domestic dogs are responsible for rabies virus transmission to humans. Yet, rabies can affect both domestic and wild an...imals. It spreads to people and animals via saliva, usually through bites, scratches or direct contact with mucosa (e.g. eyes, mouth or open wounds). Children between the age of 5 and 14 years are frequent victims.
more
No vaccines or drugs to prevent infection are available. The best way for travelers to prevent infection is to protect themselves from sand fly bites. To decrease the risk of being bitten, follow these preventive measures:
Avoid outdoor activities, especially from dusk to dawn, when sand flies ge...nerally are the most active.
more
Many vaccines and drugs hold the promise of reducing mortality and morbidity among pregnant women and infants living in low- and middle-income countries (LMICs). However, sufficient information on the safety of drugs and vaccines in pregnant women is rarely available at the time of product licensure... or approval. To account for this, active safety surveillance efforts are needed during the post-licensure and post-approval
phase to assess the safety of drugs and vaccines in pregnant women and their offspring. Pregnancy exposure registries (PER) are used to monitor the safety of vaccines and drugs. PERs are observational studies that systematically collect health information on exposure to medical products such as drugs and vaccines during pregnancy. This review demonstrates that a number of resources presently exist in LMICs that perform active safety surveillance in pregnant populations. These results indicate such systems employ a wide variety of approaches, each with their own set of strengths and challenges, as summarized in the final section of the report.
more
This guidance describes the methods and processes of the Strategic Advisory Group of Experts (SAGE) on Immunization in developing evidence-based recommendations, WHO vaccine position papers, and other immunization policy guidance. Its aim is to facilitate the work of SAGE, its working groups and the... WHO Secretariat, as well as to inform a wider readership, such as national immunization managers and national immunization technical advisory groups. The document will be updated, as necessary, as the methodology for evidence-based decision making evolves.
more